CoagulationDisorders near Montvale, NJ

Biography: Dr. Amengual is the Herbert Irving Associate Professor of Medicine in the Division of Hematology and Oncology, Center for Lymphoid Malignancies, and Hebert Irving Comprehensive Cancer Center here at Columbia University Irving Medical Center. Dr. Amengual obtained a degree in Nutritional Sciences at Cornell University where she graduated with honors. She attained her Medical Doctorate from New York Medical College, followed by a residency in Internal Medicine at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Amengual then went on to complete her fellowship in Hematology and Oncology at the NYU Langone Medical Center, where she participated in the Physician-Scientist Training Program and graduated as a Dean's Scholar. She is the recipient of several awards and scholarships for her research, including the Irving Scholarship, the Gabrielle's Angel Foundation for Cancer Research and as a Scholar of the Amos Medical Faculty Development Award Robert Wood Johnson Foundation and the American Society of Hematology. She was also selected to participate in the prestigious American Association for Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Vail Workshop Methods in Clinical Cancer Research, the European Hematology Association/American Society of Hematology Translational Research Training Program and the South West Oncology Group (SWOG) Leadership Academy. These competitive programs select the most promising faculty for enriched development and have laid the foundation for her research. She has now served on the faculty or review committee of several of these programs. As an R01-funded physician-scientist, Dr. Amengual is focused on translating the latest scientific discoveries regarding cancer cell behavior into novel treatment platforms. She aims to translate observations and concepts developed in the laboratory directly into patient care. Specifically, she is focused on combination epigenetic targeting for both B-cell and T-cell lymphomas. She continues to develop new pharmacologic strategies directed at altering these diseases at their genetic roots, now collaborating with investigators from backgrounds of diverse scientific expertise. Dr. Amengual has been studying the effects HDAC inhibitors in combination with EZH2 inhibitors to capitalize on two common mutations driving growth of diffuse large B-cell lymphoma cells. In addition, she has studied targeting the BCL6:p53 pathway in order to shift the balance of oncogene and tumor suppressor function using novel therapeutic approaches. For T-cell lymphoma Dr. Amengual has led a clinical trial combining HDAC inhibitors with the novel antifolate drug, pralatrexate. The pralatrexate plus romidepsin combination has led to dramatic responses in patients with relapsed T-cell lymphoma and will serve as the basis of more trials to come aimed at improving outcomes with patients with these diseases. Building on these discoveries, Dr. Amengual is now evaluating the interplay of epigenetics with immune surveillance and endogenous retroviral expression in the setting of lymphoma. Dr. Amengual has lectured at academic institutions and conferences around the world, and at forums such as the Lymphoma Research Foundation and the American Hematology Society's Highlights of ASH. She has published numerous chapters and peer reviewed articles on the biology and treatment of lymphoma, and serves as a Scientific Reviewer for a number of journals in the field, including Journal of Clinical Oncology and as an Editorial Board Member of Clinical Cancer Research. She has sat on grant review and abstract review committees for meetings such as the American Society of Hematology where she has also chaired sessions, American Society of Clinical Oncology and the Doris Duke Charitable Foundation. She is actively involved in the NCI's National Clinical Trial Network, SWOG, as a Lymphoma Working Group Committee Member. Dr. Amengual is involved in numerous clinical trials for lymphoma, enabling our patients to access the best opportunities for the treatment of their disease. Dr. Amengual has clinical expertise in lymphoma, HIV- and EBV-related hematologic illnesses.

Biography: Dr. Marianna Debenedictis, MD is an Oncology Specialist who practices in Newark, NJ. She is 44 years old and has been practicing for 11 years. Dr. Marianna Debenedictis, MD is affiliated with Newark Beth Israel Medical Center.

Biography: Dr. Wendy Warren, MD is a Maternal-Fetal Medicine Specialist who practices in Livingston, NJ. She is 70 years old. Dr. Wendy Warren, MD is affiliated with Cooperman Barnabas Medical Center.

Biography: Dr. Anupama Goel, MD is a Hematology Specialist who practices in New York, NY. She is 52 years old and has been practicing for 28 years. Dr. Anupama Goel, MD is affiliated with Mount Sinai Hospital and Mount Sinai Morningside.

Care Philosophy: The journey of every patient with cancer is tough We can help them through it with compassionate care and shared decision making Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Biography: Juliet Barker, MBBS (Hons), FRACP, is an Australian trained hematologist. Having been an Attending Member and Physician at Memorial Sloan Kettering Cancer Center (MSKCC) and the Director of the MSKCC Cord Blood (CB) Transplantation Program, Dr. Barker has been recruited to Weill Cornell Medicine and NewYork-Presbyterian Hospital as the Director of the Bone Marrow Transplant and Cellular Therapy Program.Over the last 25 years, Dr. Barker has worked to expand transplant access to minority patients with hematologic malignancies and has demonstrated the ability of cord blood transplantation to provide curative therapy for such populations without suitable adult donors. Dr. Barker's work in this area has been internationally recognized and she has published extensively concerning novel strategies to optimize access to donor transplants and cord blood transplant outcomes. Additionally, she has a special focus on optimizing complex health care delivery such as hematopoietic stem cell transplantation in under-served populations. Dr. Barker has advised the National Marrow Donor Program (NMDP) and is a member of the Advisory Council on Blood Stem Cell Transplantation to the Health Resources and Services Administration of the U.S. government. She has served on the American Society for Transplantation and Cellular Therapy (ASTCT) Board and led the national ASTCT Cord Blood Special Interest Group. Having previously served as Associate Vice Chair, Faculty Development, in the Department of Medicine at MSKCC, Dr. Barkeralso has a keen interest in academic mentorship.